**Supplementary Table 1:** Clinical and imaging data in eyes affected by central retinal vein occlusion and branch retinal vein occlusion

| Subgroup | CRVO | BRVO | Controls |
|----------|------|------|----------|
| N. of Patients | 56   | 47   | 50       |
| AGE      | 60 ± 13 | 67 ± 10 | 60 ± 10 |
| Baseline LogMAR BCVA | 0.41 ± 0.33 | 0.39 ± 0.25 | 0.0 ± 0.0 |
| Final LogMAR BCVA | 0.20 ± 0.26 | 0.19 ± 0.22 | 0.0 ± 0.0 |
| Baseline CMT | 511 ± 214 | 482 ± 178 | 241 ± 11 |
| Final CMT | 328 ± 105 | 321 ± 78  | 241 ± 11 |
| mSCP VD | 0.39 ± 0.02 | 0.35 ± 0.04 | 0.49 ± 0.01 |
| mDCP VD | 0.35 ± 0.04 | 0.36 ± 0.04 | 0.49 ± 0.01 |
| mCC VD | 0.49 ± 0.01 | 0.49 ± 0.01 | 0.50 ± 0.01 |
| RPC VD | 0.41 ± 0.03 | 0.41 ± 0.02 | 0.44 ± 0.01 |
| nSCP VD | 0.31 ± 0.02 | 0.31 ± 0.01 | 0.40 ± 0.02 |
| nDCP VD | 0.50 ± 0.02 | 0.51 ± 0.03 | 0.54 ± 0.03 |

| p Values | 1 vs 2 | 1 vs 3 | 2 vs 3 |
|----------|--------|--------|--------|
| N. of Patients | p>0.05 | p>0.05 | p>0.05 |
| AGE | p>0.05 | p>0.05 | p>0.05 |
| Baseline LogMAR BCVA | p<0.01* | p<0.01* | p<0.01* |
| Final LogMAR BCVA | p>0.05 | p>0.05 | p<0.01* |
| Baseline CMT | p>0.05 | p>0.05 | p<0.01* |
| Final CMT | p>0.05 | p>0.05 | p<0.01* |
| mSCP VD | p<0.01* | p=0.007* | p<0.01* |
| mDCP VD | p<0.01* | p<0.01* | p<0.01* |
| mCC VD | p>0.05 | p>0.05 | p<0.01* |
| RPC VD | p>0.05 | p>0.05 | p<0.01* |
| nSCP VD | p>0.05 | p>0.05 | p<0.01* |
| nDCP VD | p>0.05 | p>0.05 | p<0.01* |
| nCC VD | p<0.01* | p<0.01* | p<0.01* |

Legend: CRVO: central retinal vein occlusion; BRVO: branch retinal vein occlusion; BCVA: best-corrected visual acuity; CMT: central macular thickness; SCP: superficial capillary plexus; DCP: deep capillary plexus; CC: choriocapillaris; RCP: radial peripapillary capillaries; VD: vessel density; macular plexa are indicated by “m”, whereas optic nerve head plexa are indicated by “n”. Statistically significant differences are marked by asterisks (*).